76 related articles for article (PubMed ID: 10706460)
1. Influence of low dose rIL-2 treatment on endogenous cytokine production, expression of surface IL-2R and the level of soluble IL-2R in patients with minimal residual disease.
Dmoszyńska A; Kandefer-Szerszeń M; Roliński J; Legieć W; Kamińska T
Leuk Lymphoma; 1999 Oct; 35(3-4):355-66. PubMed ID: 10706460
[TBL] [Abstract][Full Text] [Related]
2. Modulating effect of interleukin 2 therapy on interferon production by blood leukocytes of patients with minimal residual hematological disease.
Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Szuster-Ciesielska A
Arch Immunol Ther Exp (Warsz); 1997; 45(2-3):177-81. PubMed ID: 9597084
[TBL] [Abstract][Full Text] [Related]
3. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Rzeski W
Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):443-8. PubMed ID: 9437500
[TBL] [Abstract][Full Text] [Related]
4. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
[TBL] [Abstract][Full Text] [Related]
5. Membrane-bound/soluble IL-2 receptor (IL-2R) and levels of IL-1 alpha, IL-2, and IL-6 in the serum and in the PBMC culture supernatants from 17 patients with hematological malignancies.
Mantovani G; Macciò A; Lai P; Ghiani M; Turnu E; Del Giacco GS
Cell Biophys; 1995 Aug; 27(1):1-14. PubMed ID: 7493395
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
Lissoni P; Bolis S; Brivio F; Fumagalli L
Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
[TBL] [Abstract][Full Text] [Related]
7. T cells activate the tumor necrosis factor-alpha system during hemodialysis, resulting in tachyphylaxis.
van Riemsdijk IC; Baan CC; Loonen EH; Knoop CJ; Navarro Betonico G; Niesters HG; Zietse R; Weimar W
Kidney Int; 2001 Mar; 59(3):883-92. PubMed ID: 11231343
[TBL] [Abstract][Full Text] [Related]
8. Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma.
Freedman RS; Gibbons JA; Giedlin M; Kudelka AP; Kavanagh JJ; Edwards CL; Carrasco CH; Nash MA; Platsoucas CD
J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):443-51. PubMed ID: 9041464
[TBL] [Abstract][Full Text] [Related]
9. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
10. The role of tumor-associated macrophages on serum soluble IL-2R levels in B-cell lymphomas.
Sakai A; Yoshida N
J Clin Exp Hematop; 2014; 54(1):49-57. PubMed ID: 24942946
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
[TBL] [Abstract][Full Text] [Related]
12. Serum interleukin-2 (IL-2), soluble IL-2 receptors and tumor necrosis factor-alfa levels are significantly increased in acute myeloid leukemia patients.
Cimino G; Amadori S; Cava MC; De Sanctis V; Petti MC; Di Gregorio AO; Sgadari C; Vegna L; Cimino G; Mandelli F
Leukemia; 1991 Jan; 5(1):32-5. PubMed ID: 1999955
[TBL] [Abstract][Full Text] [Related]
13. Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients.
Kasid A; Director EP; Rosenberg SA
J Immunol; 1989 Jul; 143(2):736-9. PubMed ID: 2661690
[TBL] [Abstract][Full Text] [Related]
14. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
15. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
[TBL] [Abstract][Full Text] [Related]
16. Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas. An immunocytochemical study.
Ruco LP; Pomponi D; Pigott R; Stoppacciaro A; Monardo F; Uccini S; Boraschi D; Tagliabue A; Santoni A; Dejana E
Am J Pathol; 1990 Nov; 137(5):1163-71. PubMed ID: 1700619
[TBL] [Abstract][Full Text] [Related]
17. Serum interleukin 2 and soluble interleukin 2 receptor in chronic active hepatitis C: effect of interferon therapy.
Simsek H; Kadayifci A
J Int Med Res; 1996; 24(3):239-45. PubMed ID: 8725984
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2.
Fortis C; Soldini L; Ghezzi S; Colombo S; Tambussi G; Vicenzi E; Gianotti N; Nozza S; Veglia F; Murone M; Lazzarin A; Poli G
AIDS Res Hum Retroviruses; 2002 May; 18(7):491-9. PubMed ID: 12015902
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus-infected adherent cell-derived inhibitory factor (p29) inhibits normal T cell proliferation through decreased expression of high affinity interleukin-2 receptors and production of interleukin-2.
Ammar A; Sahraoui Y; Tsapis A; Bertoli AM; Jasmin C; Georgoulias V
J Clin Invest; 1992 Jul; 90(1):8-14. PubMed ID: 1321845
[TBL] [Abstract][Full Text] [Related]
20. [A study of cytokine expression in peripheral blood of patients with Graves' ophthalmopathy].
Tang L; Luo Q; Zhou X; Xia R
Zhonghua Yan Ke Za Zhi; 2002 Mar; 38(3):165-7. PubMed ID: 11955323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
